Education
About Us
Working with TipRanks
Follow Us
Valneva Se (VALN)
:VALN
VALN Stock Chart & Stats
$8.82
$0.03(0.64%)
At close: 4:00 PM EST
$8.82
$0.03(0.64%)
Day’s Range― - ―
52-Week Range$3.62 - $12.25
Previous CloseN/A
Volume18.63K
Average Volume (3M)24.42K
Market Cap
$811.36M
Enterprise Value$1.11B
Total Cash (Recent Filing)$161.31M
Total Debt (Recent Filing)$196.92M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 19, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding85,979,140
10 Day Avg. Volume21,581
30 Day Avg. Volume24,416
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)1.64
Price to Sales (P/S)1.75
P/FCF Ratio-3.54
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue5.65
Enterprise Value/Gross Profit11.52
Enterprise Value/Ebitda-27.07
Forecast
1Y Price Target
$15.50Price Target Upside75.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Investment OpportunityThe pullback creates a buying opportunity ahead of Lyme data, which is viewed as a high probability of success event.
Product DevelopmentThe largest value driver for VALN going forward remains VLA15, the company’s Phase 3 Lyme disease vaccine candidate being co-developed globally with Pfizer.
Risk-Reward ProfileVLA15 alone underpins a favorable risk-reward profile for VALN shares, with additional optionality provided by Valneva’s broader commercial portfolio and early-stage pipeline.
Bears Say
Development And Execution RisksKey risks include VLA15 development or regulatory delays, commercial execution risk for IXCHIQ and future launches, and the need for additional funding if milestone or royalty income falls short of projections.
Regulatory ChallengesThe FDA has suspended the license for IXCHIQ following four new reports of serious adverse events, requiring Valneva to halt all shipments and sales of IXCHIQ in the U.S.
Regulatory RisksThere is some potential risk for ex-U.S. regulators to change stance on Ixchiq licensure.
Valneva News
VALN FAQ
What was Valneva Se’s price range in the past 12 months?
Valneva Se lowest stock price was $3.62 and its highest was $12.25 in the past 12 months.
What is Valneva Se’s market cap?
Valneva Se’s market cap is $811.36M.
When is Valneva Se’s upcoming earnings report date?
Valneva Se’s upcoming earnings report date is Mar 19, 2026 which is in 103 days.
How were Valneva Se’s earnings last quarter?
Valneva Se released its earnings results on Nov 20, 2025. The company reported -$0.561 earnings per share for the quarter, missing the consensus estimate of -$0.357 by -$0.204.
Is Valneva Se overvalued?
According to Wall Street analysts Valneva Se’s price is currently Undervalued.
Does Valneva Se pay dividends?
Valneva Se does not currently pay dividends.
What is Valneva Se’s EPS estimate?
Valneva Se’s EPS estimate is -0.33.
How many shares outstanding does Valneva Se have?
Valneva Se has 85,979,140 shares outstanding.
What happened to Valneva Se’s price movement after its last earnings report?
Valneva Se reported an EPS of -$0.561 in its last earnings report, missing expectations of -$0.357. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of Valneva Se?
Currently, no hedge funds are holding shares in VALN
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (75.74% Upside)
$15.50 (75.74% Upside)
Blogger Sentiment
Neutral
VALN Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.50%
12-Months-Change
Fundamentals
Return on Equity
-54.42%
Trailing 12-Months
Asset Growth
-8.65%
Trailing 12-Months
Company Description
Valneva Se
Valneva SE is a biotechnology company focused on developing and commercializing innovative vaccines for infectious diseases. Headquartered in Lyon, France, Valneva operates in the pharmaceutical sector, with a particular emphasis on vaccine development for diseases such as Lyme disease, COVID-19, and chikungunya. The company's core products include its proprietary inactivated vaccine for Japanese encephalitis and a COVID-19 vaccine candidate, among others. Valneva's mission is to address unmet medical needs by leveraging its expertise in vaccine technology.
VALN Company Deck
VALN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The company showed positive developments in revenue growth and cash management, along with promising clinical advancements. However, challenges remain with IXCHIQ sales suspension, DUKORAL sales decline, and operating losses.View all VALN earnings summariesVALN Stock 12 Month Forecast
Average Price Target
$15.50
▲(75.74% Upside)
Technical Analysis
Arbutus Biopharma
―
Urogen Pharma
―
Inventiva
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Ownership Overview
―
Insiders
0.14% Mutual Funds
5.84% Other Institutional Investors
94.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---